Cardio Diagnostics (NASDAQ:CDIO) vs. TNF Pharmaceuticals (NASDAQ:TNFA) Head to Head Review

TNF Pharmaceuticals (NASDAQ:TNFA) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Insider & Institutional Ownership

9.6% of TNF Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 1.2% of TNF Pharmaceuticals shares are owned by company insiders. Comparatively, 22.3% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

TNF Pharmaceuticals has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 3.61, meaning that its stock price is 261% more volatile than the S&P 500.

Profitability

This table compares TNF Pharmaceuticals and Cardio Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TNF Pharmaceuticals	N/A	-180.71%	-84.27%
Cardio Diagnostics	-22,732.03%	-258.85%	-191.20%

Earnings & Valuation

This table compares TNF Pharmaceuticals and Cardio Diagnostics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TNF Pharmaceuticals	N/A	N/A	-$4.00 million	N/A	N/A
Cardio Diagnostics	$34,890.00	456.59	-$8.38 million	N/A	N/A

TNF Pharmaceuticals has higher earnings, but lower revenue than Cardio Diagnostics.

Analyst Recommendations

This is a breakdown of recent ratings for TNF Pharmaceuticals and Cardio Diagnostics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TNF Pharmaceuticals	0	0	0	0	0.00
Cardio Diagnostics	0	0	1	0	3.00

Cardio Diagnostics has a consensus price target of $2.00, indicating a potential upside of 554.66%. Given Cardio Diagnostics’ stronger consensus rating and higher possible upside, analysts clearly believe Cardio Diagnostics is more favorable than TNF Pharmaceuticals.

Summary

Cardio Diagnostics beats TNF Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About TNF Pharmaceuticals

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.